CLK1 had been considered as a novel therapeutic target in GC through phosphoproteomic analysis, and facilitated the proliferation, migration and invasion of GC cells via modulation of the phosphorylation of SRSF2 [29]. Here, CLK1 is linked to gastric cancer.